Two Biotech Stocks Hit Record Highs on Impressive New Drug Data

Shares of biotech companies Roivant and Pharvaris surged to record highs on Tuesday, following the release of highly positive trial results for their respective therapies targeting lung disease and swelling disorders. The stock rallies were attributed to the outstanding performance and potential of these drugs, with one analyst describing the results as a "blowout" and a "bullish scenario." The remarkable successes of these biotech firms captured investor attention, driving their shares significantly higher.